Which has preferable earnings and valuation, PYXS or ALMS?

Pyxis Oncology has higher earnings, but lower revenue than Alumis. Pyxis Oncology is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pyxis Oncology $13.86M 20.04 -$79.62M -$1.41 N/A Alumis $24.05M 41.82 -$243.32M -$3.86 N/A

Is PYXS or ALMS more profitable?

Pyxis Oncology has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Alumis -5,933.46% -93.15% -74.50%

Does the media prefer PYXS or ALMS?

In the previous week, Alumis had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for Alumis and 3 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.74 beat Alumis' score of 0.41 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, SVRA or PYXS?

Pyxis Oncology has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Savara N/A N/A -$118.84M -$0.58 N/A Pyxis Oncology $13.86M 20.04 -$79.62M -$1.41 N/A

Is SVRA or PYXS more profitable?

Savara's return on equity of -90.28% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -90.28% -68.95% Pyxis Oncology N/A -215.23% -112.19%

Does the media refer more to SVRA or PYXS?

In the previous week, Pyxis Oncology had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Pyxis Oncology and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Pyxis Oncology's score of 0.74 indicating that Savara is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PYXS or CRVS more profitable?

Corvus Pharmaceuticals' return on equity of -36.15% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% Corvus Pharmaceuticals N/A -36.15% -33.62%

Does the media prefer PYXS or CRVS?

In the previous week, Pyxis Oncology had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Corvus Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.74 beat Corvus Pharmaceuticals' score of -0.07 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CVAC or PYXS?

Pyxis Oncology has a consensus target price of $8.75, suggesting a potential upside of 162.76%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than CureVac. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CureVac 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70

Which has higher earnings & valuation, CVAC or PYXS?

CureVac has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Pyxis Oncology $13.86M 20.04 -$79.62M -$1.41 N/A

Is CVAC or PYXS more profitable?

CureVac has a net margin of 199.92% compared to Pyxis Oncology's net margin of 0.00%. CureVac's return on equity of -23.03% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Pyxis Oncology N/A -215.23% -112.19%

Is PYXS or MLTX more profitable?

MoonLake Immunotherapeutics' return on equity of -82.53% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -215.23% -112.19% MoonLake Immunotherapeutics N/A -82.53% -58.17%

Does the media refer more to PYXS or MLTX?

In the previous week, Pyxis Oncology and Pyxis Oncology both had 3 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Pyxis Oncology's score of 0.74 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pyxis Oncology (PYXS) Competitors

$3.33 -0.08 (-2.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.07 (+2.16%)

As of 09/18/2026 07:56 PM Eastern

Compare

PYXS vs. ALMS, SVRA, CRVS, CVAC, and MLTX

Should you buy Pyxis Oncology stock or one of its competitors? Pyxis Oncology's main competitors and comparable companies include Alumis (ALMS), Savara (SVRA), Corvus Pharmaceuticals (CRVS), CureVac (CVAC), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Pyxis Oncology compare to Alumis?

Pyxis Oncology (NASDAQ:PYXS) and Alumis (NASDAQ:ALMS) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

39.1% of Pyxis Oncology shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Alumis had 3 more articles in the media than Pyxis Oncology. MarketBeat recorded 6 mentions for Alumis and 3 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.74 beat Alumis' score of 0.41 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pyxis Oncology currently has a consensus target price of $8.75, indicating a potential upside of 162.76%. Alumis has a consensus target price of $33.27, indicating a potential upside of 328.22%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Alumis	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Pyxis Oncology has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Alumis has a beta of -0.81, meaning that its stock price is 181% less volatile than the broader market.

Pyxis Oncology has higher earnings, but lower revenue than Alumis. Pyxis Oncology is trading at a lower price-to-earnings ratio than Alumis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A
Alumis	$24.05M	41.82	-$243.32M	-$3.86	N/A

Pyxis Oncology has a net margin of 0.00% compared to Alumis' net margin of -5,933.46%. Alumis' return on equity of -93.15% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Alumis	-5,933.46%	-93.15%	-74.50%

Summary

Alumis beats Pyxis Oncology on 11 of the 17 factors compared between the two stocks.

How does Pyxis Oncology compare to Savara?

Savara (NASDAQ:SVRA) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

87.9% of Savara shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pyxis Oncology had 2 more articles in the media than Savara. MarketBeat recorded 3 mentions for Pyxis Oncology and 1 mentions for Savara. Savara's average media sentiment score of 1.02 beat Pyxis Oncology's score of 0.74 indicating that Savara is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.58	N/A
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A

Savara's return on equity of -90.28% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-90.28%	-68.95%
Pyxis Oncology	N/A	-215.23%	-112.19%

Savara has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, indicating that its stock price is 34% more volatile than the broader market.

Savara currently has a consensus price target of $10.00, suggesting a potential upside of 86.22%. Pyxis Oncology has a consensus price target of $8.75, suggesting a potential upside of 162.76%. Given Pyxis Oncology's higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

Summary

Pyxis Oncology beats Savara on 8 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to Corvus Pharmaceuticals?

Pyxis Oncology (NASDAQ:PYXS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

Corvus Pharmaceuticals' return on equity of -36.15% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Pyxis Oncology presently has a consensus price target of $8.75, suggesting a potential upside of 162.76%. Corvus Pharmaceuticals has a consensus price target of $33.33, suggesting a potential upside of 165.39%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pyxis Oncology had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 3 mentions for Pyxis Oncology and 2 mentions for Corvus Pharmaceuticals. Pyxis Oncology's average media sentiment score of 0.74 beat Corvus Pharmaceuticals' score of -0.07 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corvus Pharmaceuticals has lower revenue, but higher earnings than Pyxis Oncology. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Pyxis Oncology has a beta of 1.34, indicating that its share price is 34% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Summary

Corvus Pharmaceuticals beats Pyxis Oncology on 9 of the 15 factors compared between the two stocks.

How does Pyxis Oncology compare to CureVac?

CureVac (NASDAQ:CVAC) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

In the previous week, Pyxis Oncology had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Pyxis Oncology and 0 mentions for CureVac. Pyxis Oncology's average media sentiment score of 0.74 beat CureVac's score of 0.00 indicating that Pyxis Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Pyxis Oncology	Positive

CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Pyxis Oncology has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

Pyxis Oncology has a consensus target price of $8.75, suggesting a potential upside of 162.76%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, analysts plainly believe Pyxis Oncology is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

CureVac has a net margin of 199.92% compared to Pyxis Oncology's net margin of 0.00%. CureVac's return on equity of -23.03% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Pyxis Oncology	N/A	-215.23%	-112.19%

CureVac has higher revenue and earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A

17.3% of CureVac shares are held by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 5.7% of Pyxis Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CureVac and Pyxis Oncology tied by winning 8 of the 16 factors compared between the two stocks.

How does Pyxis Oncology compare to MoonLake Immunotherapeutics?

Pyxis Oncology (NASDAQ:PYXS) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 5.7% of Pyxis Oncology shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Pyxis Oncology has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	20.04	-$79.62M	-$1.41	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

Pyxis Oncology presently has a consensus target price of $8.75, suggesting a potential upside of 162.76%. MoonLake Immunotherapeutics has a consensus target price of $24.57, suggesting a potential upside of 98.32%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities research analysts clearly believe Pyxis Oncology is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44

Pyxis Oncology has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

In the previous week, Pyxis Oncology and Pyxis Oncology both had 3 articles in the media. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat Pyxis Oncology's score of 0.74 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics' return on equity of -82.53% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-215.23%	-112.19%
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%

Summary

Pyxis Oncology beats MoonLake Immunotherapeutics on 7 of the 13 factors compared between the two stocks.

Get Pyxis Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYXS vs. The Competition

Export

Metric	Pyxis Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$277.75M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-2.36	14.23	275.49	25.40
Price / Sales	20.04	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	3.87	15.45	10.46	6.33
Net Income	-$79.62M	-$22.86M	$3.49B	$358.33M
7 Day Performance	3.74%	-1.21%	0.59%	1.12%
1 Month Performance	6.73%	-3.29%	-1.74%	-2.39%
1 Year Performance	48.00%	37.74%	18.13%	5.35%

Pyxis Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYXS Pyxis Oncology	3.4195 of 5 stars	$3.33 -2.3%	$8.75 +162.8%	+48.0%	$277.75M	$13.86M	N/A	56
ALMS Alumis	3.939 of 5 stars	$8.36 -9.4%	$33.27 +298.2%	+86.3%	$1.08B	$7.40M	N/A	239	Analyst Forecast
SVRA Savara	2.0647 of 5 stars	$5.23 -2.2%	$10.00 +91.4%	+52.1%	$1.07B	N/A	N/A	70	Positive News
CRVS Corvus Pharmaceuticals	2.0639 of 5 stars	$12.53 -4.4%	$33.33 +166.0%	+114.0%	$1.05B	N/A	N/A	37	Analyst Forecast
CVAC CureVac	N/A	$4.66 flat	N/A	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYXS) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pyxis Oncology (PYXS) Competitors

PYXS vs. ALMS, SVRA, CRVS, CVAC, and MLTX

How does Pyxis Oncology compare to Alumis?

Summary

How does Pyxis Oncology compare to Savara?

Summary

How does Pyxis Oncology compare to Corvus Pharmaceuticals?

Summary

How does Pyxis Oncology compare to CureVac?

Summary

How does Pyxis Oncology compare to MoonLake Immunotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pyxis Oncology (PYXS) Competitors

PYXS vs. ALMS, SVRA, CRVS, CVAC, and MLTX

How does Pyxis Oncology compare to Alumis?

Do institutionals & insiders have more ownership in PYXS or ALMS?

Does the media prefer PYXS or ALMS?

Do analysts recommend PYXS or ALMS?

Which has more volatility & risk, PYXS or ALMS?

Which has preferable earnings and valuation, PYXS or ALMS?

Is PYXS or ALMS more profitable?

Summary

How does Pyxis Oncology compare to Savara?

Do institutionals and insiders believe in SVRA or PYXS?

Does the media refer more to SVRA or PYXS?

Which has preferable earnings and valuation, SVRA or PYXS?

Is SVRA or PYXS more profitable?

Which has more risk and volatility, SVRA or PYXS?

Do analysts recommend SVRA or PYXS?

Summary

How does Pyxis Oncology compare to Corvus Pharmaceuticals?

Is PYXS or CRVS more profitable?

Do analysts rate PYXS or CRVS?

Do institutionals and insiders hold more shares of PYXS or CRVS?

Does the media prefer PYXS or CRVS?

Which has higher valuation & earnings, PYXS or CRVS?

Which has more risk & volatility, PYXS or CRVS?

Summary

How does Pyxis Oncology compare to CureVac?

Does the media favor CVAC or PYXS?

Which has more volatility and risk, CVAC or PYXS?

Do analysts prefer CVAC or PYXS?

Is CVAC or PYXS more profitable?

Which has higher earnings & valuation, CVAC or PYXS?

Do institutionals & insiders hold more shares of CVAC or PYXS?

Summary

How does Pyxis Oncology compare to MoonLake Immunotherapeutics?

Do institutionals and insiders hold more shares of PYXS or MLTX?

Which has better valuation and earnings, PYXS or MLTX?

Do analysts rate PYXS or MLTX?

Which has more risk & volatility, PYXS or MLTX?

Does the media refer more to PYXS or MLTX?

Is PYXS or MLTX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS vs. The Competition

Pyxis Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools